ONTARIO, Calif., Sept. 8, 2003 (PRIMEZONE) -- LifePoint, Inc. (AMEX:LFP), a leader in non-invasive drug diagnostic technologies and solutions, today announced that Mr. Kevin McNerney has joined the Company as Vice President of Operations. Mr. McNerney will oversee product manufacturing, manufacturing engineering, materials planning and purchasing, distribution and warehousing.
"Kevin's proven track record includes major domestic and international new facility design and construction, new product development and transfer to manufacturing, product line expansion and relocation," stated Linda H. Masterson, CEO & President of LifePoint. "His successes include product automation and process scale-up, MRP implementation, and ISO 9001 certification, all critical skills that will be needed at LifePoint over the next 18 months. We are excited about the depth and breadth of experience that Kevin adds to our senior management team."
Mr. McNerney has over 20 years experience in both the medical device and pharmaceutical industries, with hands on experience in start-up organizations, although classically trained in fortune 100 companies. Since November 2000, Mr. McNerney held several key positions, including Vice President of Operations, at Power Medical Intervention. Prior to that, Mr. McNerney was Vice President of Operations at Premier Laser Systems, and Director of Corporate Engineering at Leiner Health Products. From 1994 until 1999, Mr. McNerney held various manufacturing positions at B.Braun / McGaw, including Director of SAP Integration and Director of Manufacturing Engineering. Prior to McGaw, he held various positions at Mentor Corporation, Pharmaseal Division of Baxter HealthCare, Surgikos Division of Johnson & Johnson and Kendall Company.
Mr. McNerney has an MBA from Pepperdine University and a Bachelor of Science in Mechanical Engineering from the University of Virginia.
About LifePoint, Inc.
LifePoint, Inc., a leader in non-invasive drug diagnostic technologies and solutions, has developed, manufactures and markets the IMPACT(r) Test System -- a rapid diagnostic testing, screening and drug monitoring device for use in law enforcement and the workplace, and in the future, ambulances, pharmacies, and home healthcare markets. LifePoint's patented and proprietary technologies for the use of saliva as a non-invasive, blood-comparable test specimen, used in conjunction with the flow immunosensor technology licensed from the United States Navy, have allowed LifePoint to develop a broadly applicable, rapid, on-site diagnostic test system. The first product simultaneously detects drugs of abuse and alcohol. The initial three target markets -- law enforcement, industrial workplace and medical emergency room -- are estimated to be over $1.6 billion in total opportunity.
This press release contains forward-looking statements regarding future events and the future performance of LifePoint, Inc. that involve risks and uncertainties that could cause actual results to differ materially. Although the Company believes that the expectations reflected in any forward-looking statements made herein are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company undertakes no obligation to update any forward-looking statements made to conform to actual results or to changes to expectations. These risks include, but are not limited to completion of the second close of the financing, potential need for additional financing, FDA 510(k) clearance in medical markets, the need to hire personnel, dependence on third parties for certain marketing efforts, and market acceptance. These risks and others are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
LifePoint(r) and IMPACT(r) are trademarks of LifePoint, Inc.